Brief: Bayer Says Asundexian First Factor XIa Inhibitor Approved In China
Yesterday 08:20
BRIEF-Bayer Says Asundexian First Factor XIa Inhibitor Approved In China Oct 26 (Reuters) - BAYER AG BAYGn.DE:
ASUNDEXIAN FIRST FACTOR XIA INHIBITOR APPROVED IN CHINA FOR STROKE RISK REDUCTION AFTER PRIORITY REVIEW
WITH THIS APPROVAL, ASUNDEXIAN WILL BECOME FIRST FACTOR XIA INHIBITOR (FXIA) AVAILABLE IN CHINA
TO REDUCE RISK OF STROKE IN ADULTS AFTER A NON-CARDIOEMBOLIC ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
ASUNDEXIAN HAS BEEN SUBMITTED FOR MARKETING AUTHORIZATION IN ADDITIONAL MARKETS AROUND WORLD
APPROVAL IS BASED ON POSITIVE DATA FROM GLOBAL PHASE III OCEANIC-STROKE STUDY
Further company coverage: [BAYGn.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Bayer AG
See all newsSyngenta IPO aims for valuation of at least $66 billion, sources say
Syngenta aims for valuation of at least $66 billion with IPO, sources say
China approves Bayer blood thinner asundexian
Bayer, Orion gain after positive data on prostate cancer drug Nubeqa
Brief: Bayer Says Asundexian First Factor XIa Inhibitor Approved In China